| Photo via CDC on Unsplash
The 2025-2026 flu season in the US features a surge in H3N2 cases, particularly the subclade K variant, amid declining vaccination rates that signal rising hesitancy. CDC data shows at least 7.5 million illnesses, over 3,100 deaths, and eight pediatric fatalities so far, with activity escalating nationwide. Vaccine effectiveness against H3N2 hospitalization hovers around 37%, yet experts stress vaccination as the best defense despite mismatches.
The 2025-2026 flu vaccine provides moderate protection against the dominant H3N2 strain, with CDC-linked analyses from Southern Hemisphere data estimating 37.2% effectiveness against hospitalization. Early US estimates range from 30-50% for medically attended cases, higher for severe outcomes in children and high-risk adults. Despite a partial mismatch with subclade K, vaccines reduce hospitalizations by up to 48% in some adult groups.
Flu vaccine distribution dropped to 130 million doses this season, 13 million fewer than at the same point last year, reflecting hesitancy fueled by misconceptions, such as the belief that vaccines cause the flu. Lower uptake among children (down from prior seasons) and adults correlates with surging cases, especially as the preceding year’s deadly toll—280 pediatric deaths—highlights risks. CDC urges countering myths with facts to boost coverage.
CDC recommends annual vaccination starting in September for all ages six months and older, prioritizing high-risk groups amid co-circulating viruses. Everyone, including healthy individuals, should be vaccinated; antiviral prophylaxis is recommended for unvaccinated high-risk contacts within 48 hours of exposure. Track updates on regional trends via FluView.
Cases hit children hardest, with ILI visits highest in ages 0-4 (5.1%) and pediatric deaths at eight so far, often in those under 9; 95% of hospitalized adults have comorbidities. Activity spiked nationally, with 25.6% test positivity in week 51; hospitalization rates at 22.9 per 100,000, rising in most HHS regions except the Midwest. Southern and Midwestern states exhibit variable hotspots associated with lower vaccine coverage.
“CDC recommends annual vaccination starting in September for all ages six months and older, prioritizing high-risk groups amid co-circulating viruses. Everyone, including healthy individuals, should be vaccinated; antiviral prophylaxis is recommended for unvaccinated high-risk contacts within 48 hours of exposure.”
US H3N2 surge mirrors global patterns, with subclade K driving early activity in Australia, Europe (47% of EU sequences), Japan, the UK, and Canada. Globally, it accounts for 33% of H3N2 in GISAID data; in the US, 89.8% of characterized H3N2 are K, fueling faster spread than in typical seasons. Vaccine mismatch concerns align worldwide, but US pediatric deaths outpace non-pandemic norms.
Regional H3N2 spread varies widely across US HHS regions in the 2025-2026 flu season, with Mountain states leading in test positivity and the Northeast showing the highest hospitalization burdens. All ten areas report elevated activity above baselines, driven by H3N2 (91.8% of subtyped viruses nationally). As of week 51 (ending Dec 20, 2025), national test positivity hit 25.6%, up sharply.
Region 8 (Mountain: CO, MT, ND, SD, UT, WY) tops at 34.9% positivity, followed by others with substantial increases; Region 9 (West Coast: AZ, CA, HI, NV) lags at 10.8%. All regions saw ≥0.5 percentage-point week-over-week increases, reflecting a uniform acceleration in H3N2. Virus distribution shifts regionally, with H3N2 dominant nationwide but with local subtypes varying across regions.
Admission rates per 100,000 span 1.9 (Region 10: Pacific NW: AK, ID, OR, WA) to 11.6 (Region 2: NY/NJ/PR). Cumulative FluSurv-NET rate at 18.2 per 100,000, third-highest at this point since 2010-11; 96.3% influenza A, mostly H3N2 (87.4% subtyped). Rates climb in Regions 1-5,9,10; Regions 6-8 show less consistent trends.
ILI (Influenza-like Illness) at 6.0% nationally, up in all regions and age groups; 22 states “very high,” 10 “high.” ED visits for influenza DD at 5.4%, surging across ages/regions. H3N2 subclade K fuels faster spread, with prior peaks earliest in Regions 8-10.
Antivirals such as oseltamivir (Tamiflu: 75 mg twice daily for 5 days), zanamivir, and baloxavir are effective when started within 48 hours of symptom onset; adjust for renal impairment. Use for high-risk patients or prophylaxis (e.g., oseltamivir 75 mg daily for 10 days post-exposure). Combine with rest, hydration, and fever reducers; test confirms influenza.
Do Not Become a Statistic- Flu Vaccine Still Your Best Defense.
————————————————————-
ABOUT THE AUTHOR: Dr. Crispin Fernandez advocates for overseas Filipinos, public health, transformative political change, and patriotic economics. He is also a community organizer, leader, and freelance writer.
